This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (353) MRC funded proposals with peer-review reports (UK) (2)

Published on in Vol 6, No 9 (2017): September

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Authors of this article:

Keira Annie Markey1, 2 Author Orcid Image ;   Ryan Ottridge3 Author Orcid Image ;   James L Mitchell1, 2 Author Orcid Image ;   Caroline Rick3 Author Orcid Image ;   Rebecca Woolley3 Author Orcid Image ;   Natalie Ives3 Author Orcid Image ;   Peter Nightingale4 Author Orcid Image ;   Alexandra J Sinclair1, 2 Author Orcid Image
Article Authors Cited by (35) Tweetations (10) Metrics

Journals

  1. Hoffmann J, Mollan S, Paemeleire K, Lampl C, Jensen R, Sinclair A. European Headache Federation guideline on idiopathic intracranial hypertension. The Journal of Headache and Pain 2018;19(1) View
  2. Alimajstorovic Z, Westgate C, Jensen R, Eftekhari S, Mitchell J, Vijay V, Seneviratne S, Mollan S, Sinclair A. Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. Eye 2020;34(8):1321 View
  3. Wishna A, Hurtig A, Templeton K. Eye Conditions in Women. Gender and the Genome 2020;4:247028972090710 View
  4. Sircana A, De Michieli F, Parente R, Framarin L, Leone N, Berrutti M, Paschetta E, Bongiovanni D, Musso G. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research 2019;144:390 View
  5. Mollan S, Hemmings K, Herd C, Denton A, Williamson S, Sinclair A. What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open 2019;9(3):e026573 View
  6. Burkett J, Ailani J. An Up to Date Review of Pseudotumor Cerebri Syndrome. Current Neurology and Neuroscience Reports 2018;18(6) View
  7. Virdee J, Larcombe S, Vijay V, Sinclair A, Dayan M, Mollan S. Reviewing the Recent Developments in Idiopathic Intracranial Hypertension. Ophthalmology and Therapy 2020;9(4):767 View
  8. Markey K, Mitchell J, Botfield H, Ottridge R, Matthews T, Krishnan A, Woolley R, Westgate C, Yiangou A, Alimajstorovic Z, Shah P, Rick C, Ives N, Taylor A, Gilligan L, Jenkinson C, Arlt W, Scotton W, Fairclough R, Singhal R, Stewart P, Tomlinson J, Lavery G, Mollan S, Sinclair A. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications 2020;2(1) View
  9. Mollan S, Hornby C, Mitchell J, Sinclair A. Evaluation and management of adult idiopathic intracranial hypertension. Practical Neurology 2018;18(6):485 View
  10. Grech O, Mollan S, Wakerley B, Alimajstorovic Z, Lavery G, Sinclair A. Emerging themes in idiopathic intracranial hypertension. Journal of Neurology 2020;267(12):3776 View
  11. Mollan S, Hoffmann J, Sinclair A. Advances in the understanding of headache in idiopathic intracranial hypertension. Current Opinion in Neurology 2019;32(1):92 View
  12. Ganjoo A, Tripathi A, Chetti P. Structural assessment and identification of 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Journal of Biomolecular Structure and Dynamics 2020;38(16):4928 View
  13. Hornby C, Mollan S, Botfield H, O'Reilly M, Sinclair A. Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. Journal of Neuro-Ophthalmology 2018;38(4):522 View
  14. Pushpakom S, Iorio F, Eyers P, Escott K, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery 2019;18(1):41 View
  15. Mitchell J, Mollan S, Vijay V, Sinclair A. Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. Current Opinion in Neurology 2019;32(3):422 View
  16. Hinojosa-Amaya J, Cuevas-Ramos D, Fleseriu M. Medical Management of Cushing’s Syndrome: Current and Emerging Treatments. Drugs 2019;79(9):935 View
  17. Tambuyzer E, Vandendriessche B, Austin C, Brooks P, Larsson K, Miller Needleman K, Valentine J, Davies K, Groft S, Preti R, Oprea T, Prunotto M. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery 2020;19(2):93 View
  18. Vijay V, Mollan S, Mitchell J, Bilton E, Alimajstorovic Z, Markey K, Fong A, Walker J, Lyons H, Yiangou A, Tsermoulas G, Brock K, Sinclair A. Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension. JAMA Ophthalmology 2020;138(12):1264 View
  19. Hardy R, Botfield H, Markey K, Mitchell J, Alimajstorovic Z, Westgate C, Sagmeister M, Fairclough R, Ottridge R, Yiangou A, Storbeck K, Taylor A, Gilligan L, Arlt W, Stewart P, Tomlinson J, Mollan S, Lavery G, Sinclair A. 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. The Journal of Clinical Endocrinology & Metabolism 2021;106(1):174 View
  20. Yiangou A, Mitchell J, Fisher C, Edwards J, Vijay V, Alimajstorovic Z, Grech O, Lavery G, Mollan S, Sinclair A. Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation. Headache: The Journal of Head and Face Pain 2021;61(1):157 View
  21. Weingartner M, Stücheli S, Kratschmar D, Birk J, Klusonova P, Chapman K, Lavery G, Odermatt A. The ratio of ursodeoxycholyltaurine to 7‐oxolithocholyltaurine serves as a biomarker of decreased 11β‐hydroxysteroid dehydrogenase 1 activity in mouse. British Journal of Pharmacology 2021;178(16):3309 View
  22. Gastaldelli A, Stefan N, Häring H. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64(7):1461 View
  23. Hasırcı Bayır B, Vanlı Yavuz E, Baykan B. Idiopathic intracranial hypertension: Do we diagnose and manage it appropriately in the light of current data?. Clinical Neurology and Neurosurgery 2021;208:106879 View
  24. Madugula S, John L, Nagamani S, Gaur A, Poroikov V, Sastry G. Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing. Computers in Biology and Medicine 2021;138:104856 View
  25. Abbas A, Schini M, Ainsworth G, Brown S, Oughton J, Crowley R, Cooper M, Fairclough R, Eastell R, Stewart P. Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. The Journal of Clinical Endocrinology & Metabolism 2022;107(7):2026 View
  26. Moreno M, Del Carpio – O’Donovan R. Neuroimaging in the diagnosis and treatment of intracranial pressure disorders. Neurological Sciences 2023;44(3):845 View
  27. Souza M, Costa B, Santos F, Fortini I. Update on Idiopathic Intracranial Hypertension Management. Arquivos de Neuro-Psiquiatria 2022;80(5 suppl 1):227 View
  28. Gómez C, Alimajstorovic Z, Othonos N, Winter D, White S, Lavery G, Tomlinson J, Sinclair A, Odermatt A. Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition. British Journal of Pharmacology 2024;181(5):698 View
  29. Grech O, Seneviratne S, Alimajstorovic Z, Yiangou A, Mitchell J, Smith T, Mollan S, Lavery G, Ludwig C, Sinclair A. Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache. Neurology 2022;99(16) View
  30. Patel V, Vaishnaw A, Shirbhate E, Kore R, Singh V, Veerasamy R, Rajak H. Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy. Mini-Reviews in Medicinal Chemistry 2024;24(6):588 View
  31. Ke Y, Yang R, Liu N. Comparing Open-Access Database and Traditional Intensive Care Studies Using Machine Learning: Bibliometric Analysis Study. Journal of Medical Internet Research 2024;26:e48330 View
  32. Biswal S, Mallick B. Unlocking the potential of signature-based drug repurposing for anticancer drug discovery. Archives of Biochemistry and Biophysics 2024;761:110150 View

Books/Policy Documents

  1. Sachdeva V, Singh G, Yadav G. Neuro-ophthalmic Disorders. View
  2. Johanson C, Keep R. Role of the Choroid Plexus in Health and Disease. View
  3. Jain K. Drug-induced Neurological Disorders. View